Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy
Blood Adv
.
2023 Mar 14;7(5):828-831.
doi: 10.1182/bloodadvances.2022007172.
Authors
Hussein A Abbas
1
2
,
Hanxiao Sun
1
3
,
Sherry Pierce
1
,
Rashmi Kanagal-Shamanna
4
,
Ziyi Li
5
,
Musa Yilmaz
1
,
Gautam Borthakur
1
,
Adam J DiPippo
6
,
Elias Jabbour
1
,
Marina Konopleva
1
,
Nicholas J Short
1
,
Courtney DiNardo
1
,
Naval Daver
1
,
Farhad Ravandi
1
,
Tapan M Kadia
1
Affiliations
1
Department of Leukemia, MD Anderson Cancer Center, Houston, TX.
2
Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX.
3
School of Public Health, University of Texas, Houston, TX.
4
Department of Hematopathology, MD Anderson Cancer Center, Houston, TX.
5
Department of Biostatistics, MD Anderson Cancer Center, Houston, TX.
6
Department of Pharmacy Clinical Programs, MD Anderson Cancer Center, Houston, TX.
PMID:
35405739
PMCID:
PMC9996355
DOI:
10.1182/bloodadvances.2022007172
No abstract available
MeSH terms
Aged
Humans
Leukemia, Myeloid, Acute* / drug therapy
Treatment Outcome
Grants and funding
R03 CA270725/CA/NCI NIH HHS/United States